Magnificamide is a new effective mammalian a-amylase inhibitor

Abstract

Recombinant analog of sea anemone Heteractis magnifica peptide was obtained and kinetic parameters of its interaction with mammalian -amylases were determined. Magnificamide inhibits -amylases significantly stronger than a medical drug acarbose (PrecoseTM or GlucobayTM). Magnificamide is assumed to find application as a drug for prevention and treatment of metabolic disorders and type 2 diabetes mellitus.